• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

Health Advocates Demand U-Turn In EU Trade Policy To Align With Its Health Objectives

29/09/2014 by Catherine Saez, Intellectual Property Watch Leave a Comment

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Health Action International Europe, and Oxfam today issued a briefing paper entitled, “Trading Away Access to Medicines: How the European trade agenda continues to undermine access to medicines.” The paper argues that new concerns such as the ebola virus and the threat of unchecked antimicrobial resistance show the need for a new model for financing pharmaceutical research and development. 

In particular, they asked that the members of the new European Parliament and EU member states ensure “that the incoming European Commission defends a trade and R&D [research and development] model that is coherent with its development and public health objectives.”

According to the briefing paper [pdf], the lack of vaccine or treatment for the Ebola virus, or the issue of antimicrobial resistance, highlight insufficient innovation and the need for “new ideas of how to finance pharmaceutical research and development.”

One-third of the world’s population, over 2 billion people, “do not have regular access to the essential medicines that they need,” particularly in low and middle income countries (LMICs), the groups said.

However, they remarked, “the European Commission (EC) has implemented a trade agenda that favours the commercial interests of the multinational pharmaceutical industry over the health of people in LMICs.”  Elsewhere, they cited the Transatlantic Trade and Investment Partnership (TTIP), through which, according to the groups, medicines prices could rise in Europe.

According to the paper, the EU has been “exerting pressure on LMICs to prevent the use of TRIPS [World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights] public health safeguards and flexibilities to reduce medicines prices,” and “using technical assistance programmes to further export excessive IP standards.”

They request that “a U-turn on trade and R&D policies” be undertaken in the next five years, and in particular not to introduce TRIPS-plus and investment protection measures in free trade agreements, “detrimental to access to medicines, and/or which limit the public-health space.”

 

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Related

Catherine Saez may be reached at csaez@ip-watch.ch.

Creative Commons License"Health Advocates Demand U-Turn In EU Trade Policy To Align With Its Health Objectives" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Filed Under: IP Policies, Language, Themes, Venues, Access to Knowledge/ Education, English, Europe, Finance, Health & IP, Innovation/ R&D, Lobbying, Patents/Designs/Trade Secrets, Regional Policy, Technical Cooperation/ Technology Transfer, WHO

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

IPW News Briefs

Saudis Seek Alternative Energy Partners Through WIPO Green Program

Chinese IP Officials Complete Study Of UK, European IP Law

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2021 · Global Policy Reporting

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.